Last update 11 Oct 2025

ScTIL210

Overview

Basic Info

Drug Type
TIL therapy
Synonyms
SCTIL210
Target
CD19
Action
modulators
Mechanism
CD19 modulators(B-lymphocyte antigen CD19 modulators)
Therapeutic Areas
Neoplasms
Active Indication
Malignant Solid Neoplasm
Inactive Indication
Acral Lentiginous Malignant Melanoma
Originator Organization
Beijing Institute for Cancer Research
Active Organization
Shanghai East Hospital
Inactive Organization
Beijing Chineo Medical Technology Co., LtdBeijing Chineo Medical Technology Co., Ltd
Beijing Institute for Cancer Research
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

3
Clinical Trials associated with ScTIL210
NCT04571892
/ RecruitingPhase 1/2IIT
An Open-label, Single-arm, Single-dose Escalation and Multiple-dose Expansion Clinical Study of Cell Therapy to Evaluate the Tolerance, the Pharmacokinetic Characteristics, the Safety, and the Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors
ChiCTR2000035753
/ RecruitingEarly Phase 1IIT
An open-label, single-arm, single-dose escalation and multiple-dose expansion clinical study of cell therapy to observe and to evaluate the tolerance, the pharmacokinetic characteristics, the safety, and the efficacy of ScTIL210 in the treatment of malignant solid tumors
NCT04357509
/ Unknown statusPhase 1IIT
An Open-lable,Single-arm,Single-dose Escalation and Multiple-dose Expansion Clinical Study of Cell Therapy to Observe and Evaluate the Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma
100 Clinical Results associated with ScTIL210
Login to view more data
100 Translational Medicine associated with ScTIL210
Login to view more data
100 Patents (Medical) associated with ScTIL210
Login to view more data
100 Deals associated with ScTIL210
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Malignant Solid NeoplasmPhase 2
China
Shanghai East Hospital
15 Oct 2020
Acral Lentiginous Malignant MelanomaPhase 1
China
Beijing Institute for Cancer Research
01 May 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free